Activatable Silicon-Xanthene Photosensitizer for Photodynamic Therapy of Glioblastoma
Pharmaceutics · 29.03.2026 · 18 (4) · 420
DOI: 10.3390/pharmaceutics18040420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 29.03.2026. Verfasst von Osman Karaman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Middle East Technical University, 06800 Ankara, Türkiye. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council.
Abstract (Originalsprache)
Background
Photodynamic therapy (PDT) offers a promising complementary strategy for treating glioblastoma multiforme (GBM); however, limited control over photosensitizer activation and reduced efficacy under hypoxic conditions remain significant limitations.
Methods
In this study, we present the synthesis and functional evaluation of Gal-SiX, an enzymatically activatable Si-xanthene-based activatable PDT agent designed to address these challenges. Prepared via an improved 10-step synthetic route, Gal-SiX exhibits clear turn-on fluorescence and absorbance responses upon β-galactosidase activation and efficiently generates reactive oxygen species in aqueous media.
Results
Mechanistic studies revealed that Gal-SiX enables both Type I and Type II PDT pathways, a favorable feature for GBM environments characterized by restricted oxygen availability. In vitro assays conducted on U87MG glioblastoma cells and L929 healthy fibroblasts demonstrated light-dependent cytotoxicity, with IC50 values of 3.30 μM and 7.19 μM, respectively. Gal-SiX also showed minimal dark toxicity (>80 μM) and potent light-induced cytotoxicity, yielding a phototoxicity index of 24.8 in glioblastoma cells. Confocal imaging and MTT assays consistently confirmed enzymatic activation and effective PDT response at the cellular level.
Conclusions
Overall, this work introduces the first activatable Si-xanthene-based PDT agent for glioblastoma and provides the first evidence that the Si-xanthene scaffold can support dual Type I/II phototoxicity. These results underscore Gal-SiX’s potential as a PDT platform for addressing the unique constraints of GBM biology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Middle East Technical University, 06800 Ankara, Türkiye.
- Department of Pharmacology, Ankara Medipol University, 06050 Ankara, Türkiye.
ORCID-Profile: Mehrdad Forough, Zubeyir Elmazoglu, Gorkem Gunbas
Förderung
- European Research Council
Zitieren
APA
Karaman, O., Kepil, D., Forough, M., Elmazoglu, Z., & Gunbas, G. (2026). Activatable Silicon-Xanthene Photosensitizer for Photodynamic Therapy of Glioblastoma. Pharmaceutics, 18(4), 420. https://doi.org/10.3390/pharmaceutics18040420
Vancouver
Karaman O, Kepil D, Forough M, Elmazoglu Z, Gunbas G. Activatable Silicon-Xanthene Photosensitizer for Photodynamic Therapy of Glioblastoma. Pharmaceutics. 2026;18(4):420. doi:10.3390/pharmaceutics18040420
BibTeX
@article{Karaman2026,
author = {Karaman, Osman and Kepil, Dilay and Forough, Mehrdad and Elmazoglu, Zubeyir and Gunbas, Gorkem},
title = {Activatable Silicon-Xanthene Photosensitizer for Photodynamic Therapy of Glioblastoma},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {4},
pages = {420},
doi = {10.3390/pharmaceutics18040420}
}
EUVIMED